Kazakhstan pharmacopoeia gets rights to use USP-NF standards
This article was originally published in SRA
Kazakhstan has gained a five-year renewable right to include written standards from the US Pharmacopeia-National Formulary in the country's pharmacopoeia1.
You may also be interested in...
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
New medicines under evaluation at the European Medicines Agency.
The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.